Scholar Rock Holding Corporation (SRRK)
El precio, las cifras principales y las últimas noticias, en un solo sitio.
Scholar Rock Holding Corporation (SRRK): cotización, análisis y datos
No hay datos disponibles
| Precio de compra | 40.2 |
| Capitalización de mercado | 6.83B |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | -409M |
| 0.67 | |
| -3.31 | |
| n/a | |
| -24.09 | |
| P/B (TTM) | 26.88 |
| P/S (TTM) | 0.00 |
| Fecha de resultados | Nov 12, 2026 |
| Precio de venta | 70.8 |
| Volumen | 1,065,726 |
| Volumen medio (20D) | 1,311,161 |
| Abierto | 56.62 |
| Anterior Cerrar | 55.89 |
| Rango del día | 55.27 - 58.09 |
| Rango de 52 semanas | 27.07 - 61.76 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for ...
Desempeño financiero
En 2025, los ingresos de Scholar Rock fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -377.94M, un aumento de 53.45%.
Estados financierosSorpresa de resultados
- Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.
- EPS de -0.84 falla las estimaciones por 0.00, con 14.29% Crecimiento interanual.
Los analistas proyectan ingresos de ... Actualizar
1 semana hace · Simply Wall St.
Scholar Rock (SRRK) Stock Looks Stretched On Book Value But Strong On ReturnsScholar Rock Holding stock has delivered an extremely strong multi year return, yet the latest valuation checks suggest the current share price may already be baking in a lot of optimism. After such a...
1 semana hace · Simply Wall St.
Is Scholar Rock Holding (SRRK) Fairly Valued On Its Apitegromab Regulatory Progress?Scholar Rock Holding (SRRK) updated investors after shifting apitegromab’s commercial fill finish work away from Catalent Indiana following FDA inspection issues, while confirming that the FDA is cont...
